TD Private Client Wealth’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $22.9K | Buy |
182
+38
| +26% | +$4.78K | ﹤0.01% | 966 |
|
|
2025
Q1 | $15.9K | Buy |
144
+65
| +82% | +$7.19K | ﹤0.01% | 965 |
|
|
2024
Q4 | $10.8K | Hold |
79
| – | – | ﹤0.01% | 1044 |
|
|
2024
Q3 | $9.1K | Hold |
79
| – | – | ﹤0.01% | 1066 |
|
|
2024
Q2 | $10.9K | Hold |
79
| – | – | ﹤0.01% | 1028 |
|
|
2024
Q1 | $10.9K | Buy |
79
+18
| +30% | +$2.48K | ﹤0.01% | 1029 |
|
|
2023
Q4 | $8.04K | Hold |
61
| – | – | ﹤0.01% | 1073 |
|
|
2023
Q3 | $6.86K | Sell |
61
-2
| -3% | -$225 | ﹤0.01% | 1077 |
|
|
2023
Q2 | $5.94K | Hold |
63
| – | – | ﹤0.01% | 1112 |
|
|
2023
Q1 | $6.38K | Hold |
63
| – | – | ﹤0.01% | 1086 |
|
|
2022
Q4 | $7.53K | Hold |
63
| – | – | ﹤0.01% | 1043 |
|
|
2022
Q3 | $6.69K | Buy |
63
+2
| +3% | +$212 | ﹤0.01% | 1040 |
|
|
2022
Q2 | $5.95K | Sell |
61
-27
| -31% | -$2.63K | ﹤0.01% | 1044 |
|
|
2022
Q1 | $8.25K | Buy |
+88
| New | +$8.25K | ﹤0.01% | 1059 |
|
|
2021
Q4 | – | Sell |
-15
| Closed | -$1.44K | – | 1232 |
|
|
2021
Q3 | $1.44K | Hold |
15
| – | – | ﹤0.01% | 1059 |
|
|
2021
Q2 | $1.46K | Hold |
15
| – | – | ﹤0.01% | 1064 |
|
|
2021
Q1 | $1.46K | Sell |
15
-38
| -72% | -$3.7K | ﹤0.01% | 1025 |
|
|
2020
Q4 | $5.08K | Hold |
53
| – | – | ﹤0.01% | 890 |
|
|
2020
Q3 | $5.1K | Hold |
53
| – | – | ﹤0.01% | 842 |
|
|
2020
Q2 | $6.47K | Sell |
53
-37
| -41% | -$4.51K | ﹤0.01% | 822 |
|
|
2020
Q1 | $7.79K | Buy |
90
+34
| +61% | +$2.94K | ﹤0.01% | 778 |
|
|
2019
Q4 | $6.02K | Buy |
+56
| New | +$6.02K | ﹤0.01% | 802 |
|